Alkermes Inc Drug Patent Portfolio

Alkermes Inc owns 3 orange book drugs protected by 32 US patents Given below is the list of Alkermes Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11707466 Immediate release multilayer tablet 12 Nov, 2041
Active
US11951111 Immediate release multilayer tablet 12 Nov, 2041
Active
US11273158 Aripiprazole dosing strategy 06 Apr, 2039
Active
US10016415 Aripiprazole prodrug compositions 08 Sep, 2035
Active
US10688091 Aripiprazole prodrug composition 17 Aug, 2035
Active
US10849894 Aripiprazole prodrug composition 17 Aug, 2035
Active
US11154552 Aripiprazole prodrug composition 17 Aug, 2035
Active
US10238651 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
Active
US10813928 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
Active
US11406632 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
Active
US9452131 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
Active
US9526726 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
Active
US11097006 Pharmaceutical compositions having improved storage stability 24 Oct, 2033
Active
US9193685 Pharmaceutical compositions having improved storage stability 24 Oct, 2033
Active
US9034867 Pharmaceutical compositions comprising sorbitan esters 07 Nov, 2032
Active
US10226458 Pharmaceutical compositions comprising sorbitan esters 19 Mar, 2032
Active
US8778960 Methods for treating antipsychotic-induced weight gain 13 Feb, 2032
Active
US9119848 Morphinan derivatives for the treatment of drug overdose 30 Aug, 2031
Active
US10300054 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
Active
US10716785 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
Active
US11185541 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
Active
US11241425 Composition for treating mental illness 23 Aug, 2031
Active
US11351166 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
Active
US11793805 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
Active
US9126977 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
Active
US9517235 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
Active
US8431576 Heterocyclic compounds for the treatment of neurological and psychological disorders 26 Oct, 2030
Active
US10112903 Heterocyclic compounds for the treatment of neurological and psychological disorders 24 Jun, 2030
Active
US8796276 Heterocyclic compounds for the treatment of neurological and psychological disorders 24 Jun, 2030
Active
US7262298 4-hydroxybenzomorphans 23 Nov, 2025
Active
US7956187 Method for decreasing opioid metabolism 31 Oct, 2021 Expired
US8252929 8-carboxamido-2,6-methano-3-benzazocines 31 Oct, 2021 Expired


Given below is the list of recent legal activities going on the following drug patents of Alkermes Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 27 Jun, 2024 US9526726
Payment of Maintenance Fee, 8th Year, Large Entity 13 Jun, 2024 US9517235
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jun, 2024 US10849894
Payment of Maintenance Fee, 4th Year, Large Entity 29 Apr, 2024 US10813928
Maintenance Fee Reminder Mailed 15 Apr, 2024 US8252929
Mail Patent eGrant Notification 09 Apr, 2024 US11951111
Recordation of Patent eGrant 09 Apr, 2024 US11951111
Recordation of Patent Grant Mailed 09 Apr, 2024 US11951111
Patent Issue Date Used in PTA Calculation 09 Apr, 2024 US11951111
Patent eGrant Notification 09 Apr, 2024 US11951111
Email Notification 09 Apr, 2024 US11951111
Payment of Maintenance Fee, 8th Year, Large Entity 27 Mar, 2024 US9452131
Email Notification 21 Mar, 2024 US11951111
Issue Notification Mailed 20 Mar, 2024 US11951111
Dispatch to FDC 08 Mar, 2024 US11951111


Alkermes Inc Drug Patents' Oppositions Filed in EPO

Alkermes Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 24, 2017, by Generics (Uk) Ltd. This opposition was filed on patent number EP12712189A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15750750A Nov, 2019 Generics (UK) Ltd Patent maintained as amended
EP10792677A Mar, 2018 Generics (UK) Ltd Patent maintained as amended
EP12712189A May, 2017 Generics (UK) Ltd Opposition rejected


Alkermes Inc's Family Patents

Alkermes Inc drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 29.0% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Alkermes Inc Drug List

Given below is the complete list of Alkermes Inc's drugs and the patents protecting them.


1. Aristada

Aristada is protected by 13 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11273158 Aripiprazole dosing strategy 06 Apr, 2039
(14 years from now)
Active
US10238651 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
(10 years from now)
Active
US10813928 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
(10 years from now)
Active
US11406632 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
(10 years from now)
Active
US9452131 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
(10 years from now)
Active
US9526726 Aripiprazole formulations having increased injection speeds 19 Mar, 2035
(10 years from now)
Active
US11097006 Pharmaceutical compositions having improved storage stability 24 Oct, 2033
(9 years from now)
Active
US9193685 Pharmaceutical compositions having improved storage stability 24 Oct, 2033
(9 years from now)
Active
US9034867 Pharmaceutical compositions comprising sorbitan esters 07 Nov, 2032
(8 years from now)
Active
US10226458 Pharmaceutical compositions comprising sorbitan esters 19 Mar, 2032
(7 years from now)
Active
US8431576 Heterocyclic compounds for the treatment of neurological and psychological disorders 26 Oct, 2030
(6 years from now)
Active
US10112903 Heterocyclic compounds for the treatment of neurological and psychological disorders 24 Jun, 2030
(5 years from now)
Active
US8796276 Heterocyclic compounds for the treatment of neurological and psychological disorders 24 Jun, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aristada's drug page


2. Aristada Initio Kit

Aristada Initio Kit is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11273158 Aripiprazole dosing strategy 06 Apr, 2039
(14 years from now)
Active
US10016415 Aripiprazole prodrug compositions 08 Sep, 2035
(10 years from now)
Active
US10688091 Aripiprazole prodrug composition 17 Aug, 2035
(10 years from now)
Active
US10849894 Aripiprazole prodrug composition 17 Aug, 2035
(10 years from now)
Active
US11154552 Aripiprazole prodrug composition 17 Aug, 2035
(10 years from now)
Active
US8431576 Heterocyclic compounds for the treatment of neurological and psychological disorders 26 Oct, 2030
(6 years from now)
Active
US10112903 Heterocyclic compounds for the treatment of neurological and psychological disorders 24 Jun, 2030
(5 years from now)
Active
US8796276 Heterocyclic compounds for the treatment of neurological and psychological disorders 24 Jun, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aristada Initio Kit's drug page


3. Lybalvi

Lybalvi is protected by 15 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11707466 Immediate release multilayer tablet 12 Nov, 2041
(17 years from now)
Active
US11951111 Immediate release multilayer tablet 12 Nov, 2041
(17 years from now)
Active
US8778960 Methods for treating antipsychotic-induced weight gain 13 Feb, 2032
(7 years from now)
Active
US9119848 Morphinan derivatives for the treatment of drug overdose 30 Aug, 2031
(6 years from now)
Active
US10300054 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
(6 years from now)
Active
US10716785 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
(6 years from now)
Active
US11185541 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
(6 years from now)
Active
US11241425 Composition for treating mental illness 23 Aug, 2031
(6 years from now)
Active
US11351166 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
(6 years from now)
Active
US11793805 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
(6 years from now)
Active
US9126977 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
(6 years from now)
Active
US9517235 Methods for treating antipsychotic-induced weight gain 23 Aug, 2031
(6 years from now)
Active
US7262298 4-hydroxybenzomorphans 23 Nov, 2025
(1 year, 1 month from now)
Active
US7956187 Method for decreasing opioid metabolism 31 Oct, 2021
(2 years ago)
Expired
US8252929 8-carboxamido-2,6-methano-3-benzazocines 31 Oct, 2021
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lybalvi's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List